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Abstract: There are four anti-tumour necrosis factor-α (TNFα) monoclonal antibodies for rheumatoid 
arthritis (RA) in Japan; infliximab (genetical recombination), adalimumab (genetical recombination), 
golimumab (genetical recombination), and certolizumab pegol (genetical recombination). The first 
monoclonal antibody for RA was infliximab (genetical recombination), approved in 2002, and the 
most recent was certolizumab pegol (genetical recombination), approved in 2012. According to the 
Review Reports of the Pharmaceuticals and Medical Devices Agency (PMDA), safety evaluations of 
these antibodies were performed. The safety evaluation of biologics is very difficult because of their 
unique and diverse structural and biological properties, species specificity, immunogenicity, and 
unpredicted immune response. RA patients tend to be treated with these antibodies for a long duration, 
and some patients are women of childbearing potential. Routine genotoxicity studies and standard 
carcinogenicity bioassays are generally inappropriate for monoclonal antibodies because the safety 
information obtained from these studies is insufficient. The International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 
has been developing harmonized guidelines in four categories: Quality, Safety, Efficacy, and 
Multidisciplinary. The S6 and M3 guidelines were revised in 2011 and 2009, respectively. One of the 
purposes of the animal experiments is to avoid adverse effects in clinical trials. The PMDA reviewers 
understood the difficulties of these safety studies, and tried to minimize the risks of these monoclonal 
antibodies. The safety evaluations of tocilizumab (genetical recombination) and etanercept (genetical 
recombination) were compared with those of anti-TNFα monoclonal antibodies. The indication and 
usage, warning and conditions for approval were evaluated. 
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2013 年 11 月現在，関節リウマチの治療に用い







伝子組換え）の承認の 2012 年までの 10 年間に，
ICH ガイドラインの改訂が進んでいる．また，新
たに合意に達したガイドラインもある．そこで，
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表 3 毒性審査から臨床使用等への提言 
































































































































































































































































表 4 承認条件の比較 






































































表 5 インフリキシマブ（遺伝子組換え）とエタネルセプト（遺伝子組換え）の承認条件の変化 
インフリキシマブ(遺伝子組換え)   
2003年 2月                          
エタネルセプト（遺伝子組換え） 
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